.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE44733

« Back to Dashboard

Claims for Patent: RE44733

Title:6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Abstract: Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p--; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block. ##STR00001##
Inventor(s): Zhang; Mingiang (Montreal, CA), Palin; Ronald (Banton, GB), Bennett; Jonathan (Edinburgh, GB)
Assignee: Merck Sharp & Dohme B.V. (Haarlem, NL)
Application Number:13/432,742
Patent Claims: 1. A 6-mercapto-cyclodextrin derivative having the general formula I ##STR00025## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof; with the exclusion of 6-per-deoxy-6-per-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-per-deoxy-6-per-(2-hydroxyethylthio)-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(carboxymethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(carboxymethylthio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis((o-carboxyphenyl)thio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-.beta.-cyclodextrin and 6-per-deoxy-6-per-(2,3-dihydroxypropylthio)-.beta.-cyclodextrin.

2. The 6-mercapto-cyclodextrin derivative according to claim 1, wherein R, m and n are defined as in claim 1 and X is COOH or SO.sub.2OH; or a pharmaceutically acceptable salt thereof.

3. The 6-mercapto-cyclodextrin derivative according to claim 1, wherein m is 0; n is 8; R is (C.sub.1-6)alkylene or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; and X is COOH or SO.sub.2OH; or a pharmaceutically acceptable salt thereof.

4. A 6-mercapto-cyclodextrin derivative according to claim 1 selected from the group consisting of: 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(3-carboxypropyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(2-carboxypropyl)thio-.gamma.-cyclodextrin; and 6-per-deoxy-6-per-(2-sulfoethyl)thio-.gamma.-cyclodextrin; or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a 6-mercapto-cyclodextrin derivative having the general formula I ##STR00026## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or a pharmaceutically acceptable salt thereof, with the exclusion of 6-per-deoxy-6-per-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-per-deoxy-6-per-(2-hydroxyethylthio)-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(carboxymethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(carboxymethylthio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis((o-carboxyphenyl)thio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-.beta.-cyclodextrin and 6-per-deoxy-6-per-(2,3-dihydroxypropylthio)-.beta.-cyclodextrin, in admixture with pharmaceutically acceptable auxilliaries.

6. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) a 6-mercapto-cyclodextrin derivative according to the general formula I ##STR00027## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or a pharmaceutically acceptable salt thereof.

7. The kit according to claim 6, wherein the neuromuscular blocking agent is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine and suxamethonium.

8. The kit according to claim 6, wherein the neuromuscular blocking agent is rocuronium.

9. A method for reversal of drug-induced neuromuscular block in a patient, which comprises parenterally administering to said patient an effective amount of a 6-mercaptocyclodextrin derivative according to the general formula I ##STR00028## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or a pharmaceutically acceptable salt thereof.

.Iadd.10. The kit according to claim 6, wherein the neuromuscular blocking agent is vecuronium..Iaddend.

.Iadd.11. 6-Per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof..Iaddend.

.Iadd.12. 6-Per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt..Iaddend.

.Iadd.13. A pharmaceutical composition comprising 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically suitable auxiliary..Iaddend.

.Iadd.14. A pharmaceutical composition comprising 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt, and a pharmaceutically suitable auxiliary..Iaddend.

.Iadd.15. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof..Iaddend.

.Iadd.16. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt..Iaddend.

.Iadd.17. The kit according to claim 15, wherein the neuromuscular blocking agent is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine and suxamethonium..Iaddend.

.Iadd.18. The kit according to claim 15, wherein the neuromuscular blocking agent is rocuronium..Iaddend.

.Iadd.19. The kit according to claim 15, wherein the neuromuscular blocking agent is vecuronium..Iaddend.

.Iadd.20. A method for reversal of drug-induced neuromuscular block in a subject, which comprises parenterally administering to said subject an effective amount of 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof..Iaddend.

.Iadd.21. A method for reversal of drug-induced neuromuscular block in a subject, which comprises parenterally administering to said subject an effective amount of 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt..Iaddend.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc